Aprea Therapeutics, Inc. (APRE)

Market Cap	25.30M
Revenue (ttm)	n/a
Net Income (ttm)	-117.98M
Shares Out	34.66M
EPS (ttm)	-1.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,894
Open	0.49
Previous Close	0.477
Day's Range	0.474 - 0.52
52-Week Range	0.331 - 4.296
Beta	0.17
Analysts	Buy
Price Target	3.06 (+521.3%)
Earnings Date	Nov 14, 2022

About APRE

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

• Industry: Biotechnology
• IPO Date: Oct 3, 2019
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: APRE

Analyst Forecast

According to 8 analysts, the average rating for APRE stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 521.32% from the latest price.

Price Target

$3.06

(521.32% upside)

Analyst Consensus: Buy